Scarica l'app Stockscreener
3.92
2.49%
-0.10
Opus Genetics Inc Borsa (IRD) Ultime notizie
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cantor Fitzgerald reiterates Opus Genetics stock rating at Overweight By Investing.com - Investing.com Canada
Price to earnings forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Wedbush Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged - TipRanks
Opus Genetics (IRD) Updates on Ongoing Clinical Trial for Eye Di - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Tenet Healthcare (THC), Opus Genetics (IRD) - The Globe and Mail
Opus Genetics expects September data from gene therapy trial By Investing.com - Investing.com India
Opus Genetics expects September data from gene therapy trial - Investing.com
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results - The Manila Times
Opus Genetics Provides Update on OPGx-BEST1 Phase 1/2 Trial and Expected September Topline Data - Quiver Quantitative
Opus Genetics set to read out BEST1 gene therapy data in September - Stock Titan
Price to earnings forward of Opus Genetics, Inc. – GETTEX:R3X1 - TradingView
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics issues 1-month pediatric gene therapy results - Ophthalmology Times Europe
Price to sales forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Price to book forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy - Ophthalmology Times Europe
symbol__ Stock Quote Price and Forecast - CNN
Opus aligns with FDA on rare eye disease gene therapy trial - BioWorld News
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $10 to $13 - Moomoo
IRD Reiterated by BTIG -- Price Target Maintained at $12.00 - GuruFocus
IRD Maintained by Chardan Capital -- Price Target Remains at $13 - GuruFocus
B.Riley reiterates Buy on Opus Genetics stock on FDA alignment By Investing.com - Investing.com South Africa
B.Riley reiterates Buy on Opus Genetics stock on FDA alignment - Investing.com
Opus Genetics stock holds Buy rating at BTIG on gene therapy progress - Investing.com Canada
Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy - Investing.com
Opus Genetics Reaches Alignment With US FDA on Phase 3 Trial of OPGx-LCA5 to Treat Retinal Disease - marketscreener.com
Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy By Investing.com - Investing.com India
Opus Genetics Reaches FDA Alignment on Phase 3 Design for OPGx-LCA5; BLA May Be Submitted Based on 6-Month Data - Quiver Quantitative
Opus Genetics clears FDA design for Phase 3 trial in childhood blindness - Stock Titan
If You Invested $1,000 in Ocuphire Pharma Inc (OCUP) - Stock Titan
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup - Yahoo Finance
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness - TipRanks
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2500 Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2000 Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2000 Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 3000E Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Microcap Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 3000E Index - marketscreener.com
Enterprise value to EBIT forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Enterprise value to EBIT forward of Opus Genetics, Inc. – DUS:R3X1 - TradingView
Opus Genetics Shares Rise on Addition to Russell Indexes - Moomoo
Opus Genetics, Inc. Actuals & Estimates (NASDAQ:IRD) - TradingView
Opus Genetics to join Russell 2000 and Russell 3000 indexes - Investing.com UK
Opus Genetics, Inc. Actuals & Estimates (FWB:R3X1) - TradingView
IRD Forecast — Price Target — Prediction for 2027 - TradingView
A2QG4Z Forecast — Price Target — Prediction for 2027 - TradingView
Opus Genetics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com Nigeria
Opus Genetics stock rises after Russell index inclusion By Investing.com - Investing.com South Africa
Opus Genetics stock rises after Russell index inclusion - Investing.com
R3X1 Forecast — Price Target — Prediction for 2027 - TradingView
Opus Genetics (IRD) Joins Key Russell Indexes Beginning June 29 - GuruFocus
Opus Genetics to Join Russell 3000, Russell 2000 and Russell Microcap Indexes - Quiver Quantitative
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):